Cross-Border M&A: Supplementary Agreements Drive Deal Structure

Alkem Medtech, a wholly-owned subsidiary of India’s Alkem Laboratories, executed a first supplementary agreement on June 26, 2026, regarding its previously announced intention to acquire a 51% to 55% stake in Occlutech Holding AG, a Swiss company. This development, following earlier intimations on February 13 and March 6, 2026, underscores a fundamental aspect of complex cross-border mergers and acquisitions: the iterative and dynamic nature of deal structuring.

Why do significant transactions, especially those spanning international borders and involving intricate assets like a medtech firm, rarely conclude with a single, definitive agreement? The answer lies in the inherent uncertainties and evolving landscapes that characterize the period between initial intent and final closure. Initial share purchase agreements often serve as foundational frameworks, establishing the core parameters while acknowledging that further adjustments will be necessary.

At its core, an acquisition involves transferring control and assets, a process that requires meticulous due diligence, regulatory clearances, and often, the satisfaction of various conditions precedent. When an acquirer, such as Alkem Medtech, aims for a majority stake of 51% to 55%, it signals a clear intent for control while potentially allowing for phased integration or the retention of minority shareholders, a common strategy in strategic partnerships. This initial agreement sets the stage, but it cannot foresee every eventuality.

This scenario exemplifies what can be termed “dynamic deal structuring.” Rather than a static, one-time contract, complex M&A often unfolds through a series of interlocking agreements. A supplementary agreement, in this framework, acts as a critical mechanism to formalize amendments, address new findings from due diligence, or incorporate changes driven by regulatory requirements or market shifts that emerge after the initial agreement’s signing. It provides the necessary flexibility to adapt the deal terms without dismantling the entire transaction.

Alkem Medtech’s execution of this first supplementary agreement for Occlutech, a Swiss entity, provides a tangible illustration of this adaptive process. The progression from the initial intimations in February and March 2026 to this latest agreement in June 2026 demonstrates how a deal evolves over several months. Such a phased approach is particularly pertinent in the highly regulated medical technology sector, where product approvals, intellectual property rights, and market access can introduce unforeseen complexities.

Many observers might view such subsequent agreements as indicative of complications or delays. However, from a structural perspective, they often signify a robust and disciplined approach to risk management. By formalizing adjustments through supplementary accords, both parties ensure that the transaction reflects the most current understanding of the asset and its environment, thereby de-risking the overall acquisition. This adaptive contracting minimizes future disputes and ensures the deal’s long-term viability.

This meticulous approach to M&A is increasingly becoming a hallmark of Indian pharmaceutical and medtech companies as they pursue global expansion. The strategic acquisition of a majority stake in a company like Occlutech Holding AG in Switzerland reflects a broader pattern of Indian entities seeking to leverage international innovation, diversify geographical presence, and integrate specialized technologies. The successful navigation of multi-stage, cross-border M&A processes is critical to realizing these strategic ambitions.

Ultimately, the execution of a supplementary agreement is less about an individual company’s immediate fortune and more about the enduring structural patterns governing sophisticated M&A. It highlights that successful integration and expansion, particularly across diverse regulatory and market landscapes, often hinges on the capacity of deal structures to adapt and formalize changes as they arise, ensuring that the initial strategic intent translates into a resilient operational reality.